Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

IDFPIsopropyl dodecylfluorophosphonate

Organophosphorus MAGL and FAAH inhibitor (IC50 0.60 to 3.0 nM for the class); it raises brain endocannabinoids in mice.

Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₁₅H₃₂FO₂P

CAS 615250-02-7

Family
ECS pharmacological toolEnzyme inhibitor
Molar mass
294.39 g/mol

Updated on

In plain terms

IDFP blocks both enzymes that destroy endocannabinoids at once. In mice their levels in the brain rise sharply and behaviour changes. It is a research tool in toxicology, chemically related to organophosphorus insecticides; no study in humans was found.

Receptors and activity

Target network

MAGLInhibitorIC50 of 0.60 to 3.0 nM in vitro for three O-alkyl alkylphosphonofluoridates (C1, C2, C3; C8, C12 chains), the class to which IDFP (O-isopropyl, C12) belongs; the value specific to IDFP is not isolated in the abstract (Quistad et al. 2006); more than ten-fold elevation of brain 2-AG in the mouse (Nomura et al. 2008)
  • Blocks or inhibits
  • Binds or modulates

The lower the cited value, the closer the target sits to IDFP: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of IDFP.

Brain, side view
Body, front view
Blood

MAGLMAGL found in 5 regions of the body

  1. CortexdenseHighest PET signal in the cerebral cortex1
  2. Basal gangliapresentModerate levels in the putamen1
  3. HippocampuspresentAxon terminals in the hippocampus2
  4. Adipose tissuepresentPresent in subcutaneous adipose tissue3
  5. Immune cellspresentRNA enhanced in blood monocytes4

Cited values

  1. MAGLInhibitorno measured value cited

    IC50 of 0.60 to 3.0 nM in vitro for three O-alkyl alkylphosphonofluoridates (C1, C2, C3; C8, C12 chains), the class to which IDFP (O-isopropyl, C12) belongs; the value specific to IDFP is not isolated in the abstract (Quistad et al. 2006); more than ten-fold elevation of brain 2-AG in the mouse (Nomura et al. 2008)

  2. FAAHInhibitorno measured value cited

    IC50 of 0.60 to 3.0 nM in vitro for the same class (Quistad et al. 2006); more than ten-fold elevation of brain anandamide in the mouse (Nomura et al. 2008); the value specific to IDFP is not isolated in the abstract

  3. CB1 (nucleophilic site)Binding (function not established)no measured value cited

    Inhibits [3H]CP 55,940 binding on mouse brain membranes, IC50 of 2 to 11 nM for three compounds including IDFP; 84% inhibition of brain binding 4 h after 30 mg/kg intraperitoneally; functional effect at CB1 not established (Segall et al. 2003)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

Isopropyl dodecylfluorophosphonate (IDFP) entered the endocannabinoid literature through toxicology. Casida's teams first described organophosphorus compounds that bind CB1 (Segall et al. 2003), then showed that alkylphosphonofluoridates inhibit MAGL and FAAH in vitro with IC50 values of 0.60 to 3.0 nM, with low selectivity (Quistad et al. 2006). In mice, dual blockade of the two enzymes by selected organophosphorus agents raises brain 2-AG and anandamide more than ten-fold and produces CB1-dependent behavioural effects that resemble those of CB1 agonists (Nomura et al. 2008). Several studies have used it as a way of raising endocannabinoid signalling: acute administration raised plasma triglycerides 2.0- to 3.1-fold in mice, an effect absent in CB1-null mice and prevented by CB1 antagonists (Ruby et al. 2008), and a single dose raised hepatic triglycerides and induced insulin resistance, partly through CB1 (Ruby et al. 2011). Suzuki and colleagues used it as a comparator for the insecticide fenitrothion: IDFP raised plasma triglycerides 4.8-fold, an effect prevented by the antagonist AM251, with no notable effect on brain acetylcholinesterase (Suzuki et al. 2014). These results are preclinical; Segall and colleagues also report delayed toxicity (mortality in 0.3 to 5 days) for this compound and two others, more closely linked to inhibition of neuropathy target esterase-lysophospholipase than to that of CB1 or acetylcholinesterase. No study in humans was found.

History

Source
An entirely synthetic compound with no natural occurrence found in the sources consulted. It is described as a research tool in toxicology and pharmacology; no human, agricultural or veterinary use was found.

Origin

Research tool

No biological pathway: IDFP is a synthetic compound of the alkylphosphonofluoridate class (organophosphorus with a fatty chain), unrelated to the plant cannabinoid pathway.

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Enzyme inhibitor

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

IDFP (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

Common name
Isopropyl dodecylfluorophosphonate
IUPAC name
1-[fluoro(propan-2-yloxy)phosphoryl]dodecane
Other names
IDFP

Identifiers

Formula
C₁₅H₃₂FO₂P
CAS
615250-02-7
InChIKey
SFRALHFBKRAJPW-UHFFFAOYSA-N
SMILES
CCCCCCCCCCCCP(=O)(OC(C)C)F

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.